fingolimod hydrochloride has been researched along with Parkinsonian Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, L; Hua, J; Li, L; Liu, L; Shi, D; Sun, X; Yao, S; Zhang, K; Zhou, H | 1 |
| Guo, Y; Han, M; Lou, H; Perez, RG; Ren, M; Shi, H; Wei, X; Zhang, X | 1 |
2 other study(ies) available for fingolimod hydrochloride and Parkinsonian Disorders
| Article | Year |
|---|---|
FTY720 Inhibits MPP
Topics: Animals; Antiparkinson Agents; Apoptosis; Cell Line; Corpus Striatum; Cytokines; Dopaminergic Neurons; Drug Evaluation, Preclinical; Exploratory Behavior; Fingolimod Hydrochloride; Inflammasomes; Male; Mice; Mice, Inbred C57BL; Microglia; Mitochondria; MPTP Poisoning; Neuroprotective Agents; NLR Family, Pyrin Domain-Containing 3 Protein; Parkinsonian Disorders; Pars Compacta; Reactive Oxygen Species; Rotarod Performance Test; Signal Transduction | 2019 |
FTY720 Attenuates 6-OHDA-Associated Dopaminergic Degeneration in Cellular and Mouse Parkinsonian Models.
Topics: Animals; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Fingolimod Hydrochloride; Humans; Male; Mice; Mice, Inbred C57BL; Nerve Degeneration; Oxidopamine; Parkinsonian Disorders | 2017 |